Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations
Embecta (EMBC) announced the publication of new global insulin injection recommendations in the Mayo Clinic Proceedings, marking the first major update in nearly 10 years. The FITTER Forward Expert Recommendations, authored by 16 diabetes specialists from 13 countries, aims to enhance clinical outcomes for diabetes patients worldwide through improved insulin injection techniques.
The recommendations focus on several key areas including: new insights on injection device technology, standardized injection techniques to prevent complications, structured training programs for healthcare providers, and patient-centered recommendations to improve therapy adherence. Led by Dr. David Klonoff, the initiative emphasizes the critical importance of proper insulin administration techniques in maintaining target blood glucose levels.
Embecta will host a webinar on April 8, 2025, at 12 pm EST featuring FITTER Forward authors to discuss the new recommendations and their clinical impact.
Embecta (EMBC) ha annunciato la pubblicazione di nuove raccomandazioni globali per le iniezioni di insulina nei Mayo Clinic Proceedings, segnando il primo importante aggiornamento in quasi 10 anni. Le Raccomandazioni FITTER Forward, redatte da 16 specialisti in diabete provenienti da 13 paesi, mirano a migliorare i risultati clinici per i pazienti diabetici in tutto il mondo attraverso tecniche di iniezione di insulina più efficaci.
Le raccomandazioni si concentrano su diversi aspetti chiave, tra cui: nuove intuizioni sulla tecnologia dei dispositivi per iniezioni, tecniche di iniezione standardizzate per prevenire complicazioni, programmi di formazione strutturati per i fornitori di assistenza sanitaria e raccomandazioni incentrate sul paziente per migliorare l'aderenza alla terapia. Guidata dal Dr. David Klonoff, l'iniziativa sottolinea l'importanza critica delle tecniche di somministrazione dell'insulina corrette per mantenere i livelli di glucosio nel sangue nei limiti target.
Embecta ospiterà un webinar l'8 aprile 2025, alle 12:00 EST, con gli autori di FITTER Forward per discutere le nuove raccomandazioni e il loro impatto clinico.
Embecta (EMBC) anunció la publicación de nuevas recomendaciones globales para la inyección de insulina en los Mayo Clinic Proceedings, marcando la primera actualización importante en casi 10 años. Las Recomendaciones FITTER Forward, redactadas por 16 especialistas en diabetes de 13 países, tienen como objetivo mejorar los resultados clínicos para los pacientes diabéticos en todo el mundo a través de técnicas mejoradas de inyección de insulina.
Las recomendaciones se centran en varias áreas clave, incluyendo: nuevas perspectivas sobre la tecnología de dispositivos de inyección, técnicas de inyección estandarizadas para prevenir complicaciones, programas de capacitación estructurados para proveedores de atención médica y recomendaciones centradas en el paciente para mejorar la adherencia a la terapia. Liderada por el Dr. David Klonoff, la iniciativa enfatiza la importancia crítica de las técnicas adecuadas de administración de insulina para mantener los niveles de glucosa en sangre dentro de los objetivos establecidos.
Embecta llevará a cabo un seminario web el 8 de abril de 2025, a las 12 p.m. EST, con los autores de FITTER Forward para discutir las nuevas recomendaciones y su impacto clínico.
엠벡타(EMBC)는 메이요 클리닉 프로시딩스에 새로운 글로벌 인슐린 주사 권장 사항을 발표했다고 밝혔으며, 이는 거의 10년 만의 첫 번째 주요 업데이트입니다. 피터 포워드 전문가 권장 사항은 13개국의 16명의 당뇨병 전문가가 저술하였으며, 전 세계 당뇨병 환자들의 임상 결과를 개선하기 위해 인슐린 주사 기술을 향상시키는 것을 목표로 하고 있습니다.
이 권장 사항은 주사 장치 기술에 대한 새로운 통찰력, 합병증 예방을 위한 표준화된 주사 기술, 의료 제공자를 위한 구조화된 교육 프로그램, 치료 순응도를 개선하기 위한 환자 중심의 권장 사항 등 여러 주요 분야에 중점을 두고 있습니다. 데이비드 클로노프 박사가 이끄는 이 이니셔티브는 목표 혈당 수치를 유지하기 위한 적절한 인슐린 투여 기술의 중요성을 강조합니다.
엠벡타는 2025년 4월 8일 오후 12시 EST에 FITTER Forward 저자들과 함께 새로운 권장 사항과 그 임상적 영향을 논의하는 웨비나를 개최할 예정입니다.
Embecta (EMBC) a annoncé la publication de nouvelles recommandations mondiales pour les injections d'insuline dans les Mayo Clinic Proceedings, marquant la première mise à jour majeure en près de 10 ans. Les Recommandations FITTER Forward, rédigées par 16 spécialistes du diabète de 13 pays, visent à améliorer les résultats cliniques pour les patients diabétiques dans le monde entier grâce à des techniques d'injection d'insuline améliorées.
Les recommandations se concentrent sur plusieurs domaines clés, notamment : de nouvelles perspectives sur la technologie des dispositifs d'injection, des techniques d'injection standardisées pour prévenir les complications, des programmes de formation structurés pour les prestataires de soins de santé et des recommandations centrées sur le patient pour améliorer l'adhérence au traitement. Dirigée par le Dr David Klonoff, l'initiative souligne l'importance cruciale des techniques appropriées d'administration de l'insuline pour maintenir les niveaux de glucose sanguin dans les objectifs fixés.
Embecta organisera un webinaire le 8 avril 2025 à 12h00 EST avec les auteurs de FITTER Forward pour discuter des nouvelles recommandations et de leur impact clinique.
Embecta (EMBC) hat die Veröffentlichung neuer globaler Empfehlungen zur Insulininjektion in den Mayo Clinic Proceedings angekündigt, was das erste große Update seit fast 10 Jahren darstellt. Die FITTER Forward Expertenempfehlungen, verfasst von 16 Diabetes-Spezialisten aus 13 Ländern, zielen darauf ab, die klinischen Ergebnisse für Diabetes-Patienten weltweit durch verbesserte Insulininjektionstechniken zu optimieren.
Die Empfehlungen konzentrieren sich auf mehrere Schlüsselbereiche, darunter: neue Erkenntnisse zur Technologie von Injektionsgeräten, standardisierte Injektionstechniken zur Vermeidung von Komplikationen, strukturierte Schulungsprogramme für Gesundheitsdienstleister und patientenorientierte Empfehlungen zur Verbesserung der Therapietreue. Unter der Leitung von Dr. David Klonoff betont die Initiative die entscheidende Bedeutung korrekter Insulinverabreichungstechniken zur Aufrechterhaltung der Zielblutzuckerwerte.
Embecta wird am 8. April 2025 um 12 Uhr EST ein Webinar mit den Autoren von FITTER Forward veranstalten, um die neuen Empfehlungen und deren klinische Auswirkungen zu diskutieren.
- Publication in prestigious Mayo Clinic Proceedings enhances company's scientific credibility
- Demonstrates leadership position in insulin delivery technology and education
- Strengthens relationships with healthcare professionals through structured training programs
- None.
First Update in Nearly 10 Years by FITTER Forward Initiative Sets Out to Transform Insulin Injection Technique Education
PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings. The publication introduces the FITTER Forward Expert Recommendations, an updated set of global best practices for insulin injection technique and education. Authored by a panel of 16 diabetes specialists from 13 countries, the FITTER Forward initiative highlights the critical need for improved training and standardization in insulin delivery, aiming to enhance clinical outcomes for millions of people with diabetes worldwide.
“When physicians and nurses discuss insulin treatments, they usually focus on the specific dose, but not so much on how exactly the insulin is administered. However, proper injection technique, proper handling of injection devices, and proper insulin handling can all significantly improve long-term glycemic control,” said Dr. David Klonoff, Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center, Clinical Professor of Medicine at UCSF, and lead author of the publication. “How insulin is injected actually plays a more crucial factor in maintaining target blood glucose levels than many realize. This new recommendation provides healthcare professionals with clear, evidence-based strategies to help ensure that insulin is delivered correctly and safely."
The Forum for Injection Technique and Therapy Expert Recommendations (FITTER) was initially developed in 2016, brought together by embecta, then part of BD (Becton, Dickinson and Company), to guide insulin administration best practices. Since then, advancements in device technology, research, and real-world patient data have warranted a major update, including:
- New insights on injection device technology, including needle length, pen needle design, width, and sharpness to help optimize patient comfort and correct insulin delivery.
- Standardized injection techniques to overcome existing gaps and help prevent complications such as lipodystrophy and inconsistent insulin absorption.
- Structured training programs for healthcare providers to equip them with practical tools for patient education.
- Patient-centered recommendations and tools to help individuals with diabetes reduce pain, overcome fear-based barriers, and improve overall adherence to insulin therapy.
"As a company dedicated to advancing diabetes care for more than 100 years, embecta is proud to support the FITTER Forward initiative," said Dr. Pasha Javadi, Senior Director, Global Medical Affairs at embecta. "Proper injection technique is a fundamental aspect of medicine delivery—whether it’s insulin, GLP-1s, or other injectable therapies. By empowering healthcare professionals with the latest research-backed recommendations, we can help improve patient outcomes and ensure that injection therapy is as effective and comfortable as possible."
The publication, entitled “Advance Insulin Injection Technique and Education with FITTER Forward Expert Recommendations,” is available in Mayo Clinic Proceedings’ April print edition and online here.
Led by four of the FITTER Forward authors, embecta will be hosting a webinar on Tuesday, April 8 at 12 pm EST to highlight the new recommendations. The webinar will also feature a panel discussion where the experts will share insights, answer questions, and discuss the publication’s potential impact in clinical practice.
Dr. Klonoff was compensated by embecta for his work on the FITTER Forward initiative.
About embecta
embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.
Contacts
Media
Christian Glazar
Sr. Director, Corporate Communications
908-821-6922
Contact Media Relations
Investors
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR
FAQ
What are the key updates in EMBC's new FITTER Forward insulin injection recommendations?
When will Embecta (EMBC) host the FITTER Forward recommendations webinar?
How many diabetes specialists contributed to EMBC's FITTER Forward recommendations?
Where are the new Embecta (EMBC) insulin injection guidelines published?
